SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-061450
Filing Date
2023-03-06
Accepted
2023-03-06 16:23:52
Documents
16
Period of Report
2023-03-03
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d458253d8k.htm   iXBRL 8-K 30776
2 EX-1.1 d458253dex11.htm EX-1.1 216243
3 EX-1.2 d458253dex12.htm EX-1.2 212238
4 EX-5.1 d458253dex51.htm EX-5.1 10596
8 GRAPHIC g458253g0301061058807.jpg GRAPHIC 2529
  Complete submission text file 0001193125-23-061450.txt   722085

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA cdtx-20230303.xsd EX-101.SCH 2834
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE cdtx-20230303_lab.xml EX-101.LAB 17993
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cdtx-20230303_pre.xml EX-101.PRE 11250
10 EXTRACTED XBRL INSTANCE DOCUMENT d458253d8k_htm.xml XML 3357
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

IRS No.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 23709246
SIC: 2836 Biological Products, (No Diagnostic Substances)